Pubovaginal Slings (Autologous Fascial Sling) — Cost, Top Hospitals & Success Rates | MyMedicPlus

The pubovaginal sling (PVS) is a well-established surgical procedure for women with stress urinary incontinence (SUI), particularly where synthetic mesh is contraindicated, where intrinsic sphincter deficiency (ISD) is the underlying pathology, or where prior continence surgery has failed. Unlike modern mid-urethral slings that use a narrow polypropylene tape positioned at the mid-urethra, the pubovaginal sling uses a strip of the patient's own autologous fascia — harvested from the rectus abdominis sheath or the fascia lata of the lateral thigh — to create a supportive hammock beneath the bladder neck and proximal urethra, restoring urethral coaptation during rises in intra-abdominal pressure.

The procedure dates to the early 20th century and was refined by McGuire and Lytton (1978) specifically for use in ISD. The landmark NIH-funded Stress Incontinence Surgical Treatment Efficacy (SISTEr) randomised controlled trial (Albo et al., 2007) compared the autologous fascial sling against Burch colposuspension in 655 women with SUI. At 24 months, overall success rates significantly favoured the sling (47% vs 38%), confirming its superiority for mixed presentations including ISD. Voiding dysfunction occurred more frequently in the sling group (14% vs 2%), underscoring the importance of patient counselling and postoperative catheterisation planning.

Following NICE's 2019 Interventional Procedures Guidance (IPG599), which restricted polypropylene mesh slings for primary SUI treatment in the UK, and the Cumberlege Review (2020) which highlighted mesh implant safety failures, the autologous pubovaginal sling has experienced significant clinical resurgence as the preferred mesh-free alternative.

The procedure is performed under general or spinal anaesthesia. A suprapubic incision allows fascial harvesting; the strip is fashioned into a sling, passed retropubically behind the pubic symphysis using long needles or a trocar system, and secured to the anterior abdominal wall fascia. Tension adjustment at the time of surgery is critical to outcome — too loose risks persistent incontinence; excessive tension causes voiding dysfunction requiring clean intermittent self-catheterisation (CISC).

The pubovaginal sling is principally indicated for stress urinary incontinence (SUI) — involuntary urinary leakage triggered by physical exertion such as coughing, sneezing, laughing, lifting, or exercise. It is particularly valuable in clinically complex presentations where simpler procedures carry limited efficacy.

• Intrinsic sphincter deficiency (ISD): Characterised by a maximal urethral closure pressure (MUCP) below 20 cmH2O or a Valsalva leak point pressure (VLPP) below 60 cmH2O on urodynamic assessment. ISD reflects poor intrinsic sphincter function rather than urethral hypermobility alone. The bladder-neck positioning of the PVS provides superior urethral coaptation compared to a mid-urethral tape in these women.
• Failed prior synthetic mid-urethral sling: Women who have undergone tension-free vaginal tape (TVT) or transobturator tape (TOT) that has failed to control SUI, or in whom synthetic tape has been removed due to erosion, chronic pain, or infection, represent a primary indication for autologous PVS as a mesh-free revision procedure.
• SUI with urethral damage or scarring: Urethral injury from prior pelvic surgery, radiation therapy, or obstetric trauma may render the urethra unresponsive to mid-urethral support. Bladder-neck slings restore proximal urethral coaptation more reliably in these anatomically challenging cases.
• SUI concurrent with pelvic organ prolapse repair: When anti-incontinence surgery is needed alongside pelvic floor reconstruction without mesh augmentation, the autologous sling can be performed concomitantly.
• Post-prostatectomy SUI (male sling adaptations): Modified autologous sling techniques are used in men with stress incontinence following radical prostatectomy, though the artificial urinary sphincter (AUS AMS 800) remains the gold standard for severe post-prostatectomy incontinence.

The pubovaginal sling is not indicated for pure urge incontinence, overactive bladder without demonstrable SUI, or detrusor overactivity as the sole cause of leakage. Accurate preoperative diagnosis through urodynamic evaluation is essential before surgical planning.

Careful patient selection through preoperative urodynamic assessment and clinical evaluation is essential to optimise surgical outcomes and minimise complications. The following criteria guide eligibility for pubovaginal sling surgery.

• Urodynamic confirmation of SUI: Urodynamic stress incontinence (USI) must be demonstrable on filling cystometry or standardised pad testing, with leakage confirmed in the absence of detrusor overactivity during the filling phase.
• Intrinsic sphincter deficiency on urodynamics: MUCP below 20 cmH2O or VLPP below 60 cmH2O supports the specific diagnosis of ISD and preferentially favours a bladder-neck sling over a mid-urethral tape, which provides inadequate urethral closure in ISD.
• Completion of conservative management: NICE NG123 (2019) requires supervised pelvic floor muscle training (PFMT) of at least 3 months duration to have been completed and found insufficient before surgical referral is appropriate.
• Prior failed synthetic sling or mesh complications: Women who have undergone previous sling surgery that failed to control incontinence, or who have experienced mesh-related complications and require removal, are strong candidates for autologous PVS as a revision or mesh-free alternative.
• NICE 2019 mesh guidance compliance: Autologous PVS entirely avoids the NHS mesh specialist centre and oversight register requirements associated with synthetic implants, simplifying the care pathway for eligible patients.
• Adequate tissue availability: Sufficient anterior rectus sheath or thigh fascia lata must be accessible for harvest — typically a strip 10–12 cm in length and 1.5–2 cm in width is required.

Relative contraindications include uncontrolled detrusor overactivity, significant post-void residual urine volume, neurogenic lower urinary tract dysfunction, poorly controlled diabetes with peripheral neuropathy, active urinary tract infection, or significant medical comorbidities precluding anaesthesia. Future pregnancy plans are also a relative contraindication, as vaginal delivery may compromise sling function.

Several surgical strategies exist for SUI management. The pubovaginal sling occupies a central role in complex, revision, and ISD-predominant cases.

• Autologous fascial PVS — rectus fascia approach: The most commonly performed variant. A 10–12 cm strip of anterior rectus abdominis fascia is harvested through a small suprapubic incision, fashioned into a sling, passed retropubically via a stamey-type needle or dedicated trocar system, and tied without excessive tension over the anterior abdominal wall fascia. No synthetic material is required.
• Autologous fascial PVS — fascia lata approach: Fascia lata is harvested from the lateral thigh using a fasciatome or open dissection. It is preferred when the rectus sheath is thin, scarred, or has been used in prior surgery. Fascia lata offers excellent tensile strength but requires a second operative field.
• Cadaveric or porcine dermal allograft slings: Used where autologous tissue is insufficient or unavailable. They provide an intermediate option between synthetic and autologous materials; however, long-term durability data are less robust than for autologous fascia.
• Burch colposuspension: Open or laparoscopic suspension of paravaginal tissue to Cooper's ligament. The SISTEr trial demonstrated lower complete success rates compared to autologous PVS (38% vs 47%) and higher rates of subsequent prolapse surgery. Suitable for women without ISD undergoing concurrent laparoscopic pelvic surgery.
• Artificial urinary sphincter (AMS 800): For women with severe ISD and near-absent sphincter function (MUCP below 10 cmH2O), particularly following pelvic radiation or multiple failed procedures, the AMS 800 provides mechanical urethral occlusion with pump-activated release. Continence rates of 80–90% are reported, but the device requires patient dexterity and long-term surveillance for mechanical failure or erosion.

Treatment selection is guided by the degree of ISD, prior surgical history, patient attitude toward mesh, surgeon experience, and the patient's ability to perform CISC should postoperative voiding dysfunction occur.

The autologous pubovaginal sling offers several evidence-based advantages, particularly for women with complex SUI, ISD, or prior failed continence surgery.

• High and durable continence rates: The SISTEr trial reported 47% complete success (no leakage episodes, no retreatment) and 80–85% overall improvement in continence at 24 months. Long-term follow-up data from multiple cohort studies (5–10 years) demonstrate sustained continence rates of 70–80%, confirming the durability of autologous PVS compared to injection therapies.
• Complete avoidance of synthetic mesh: The use of autologous fascia entirely eliminates the risk of polypropylene mesh-related complications — vaginal or urethral erosion, chronic pelvic pain, dyspareunia, and the need for complex mesh excision surgery. This is a critical benefit following the NICE 2019 restrictions and the Cumberlege Review's identification of mesh complications as a major patient safety concern affecting thousands of women.
• Superior efficacy in ISD: The bladder-neck positioning of the autologous sling provides better urethral coaptation and functional urethral lengthening than mid-urethral tapes, making it specifically effective for women with reduced intrinsic sphincter function (MUCP below 20 cmH2O).
• Feasibility in revision and complex cases: The autologous sling can be placed reliably even in the presence of urethral scarring, prior retropubic dissection, or radiation changes — situations where synthetic sling placement carries high complication and failure rates.
• Sustained quality-of-life improvement: Studies consistently report clinically significant improvements in validated QoL instruments including the Urogenital Distress Inventory (UDI-6) and Incontinence Impact Questionnaire (IIQ-7) following autologous sling surgery, with benefits persisting beyond 5 years in most patients.

Current NICE, EAU, and AUA guidelines all recommend the autologous pubovaginal sling as a first-choice surgical option for women with ISD and as a preferred revision procedure after failed synthetic slings.

While generally safe in experienced hands, the pubovaginal sling carries procedural risks that require thorough preoperative counselling. Complications arise both from the sling placement itself and from the fascial harvest site.

• Voiding dysfunction (10–25%): The most clinically significant complication. Excessive sling tension or postoperative oedema at the bladder neck causes incomplete bladder emptying, urinary hesitancy, or acute retention. The SISTEr trial reported voiding dysfunction requiring intervention in 14% of sling patients vs 2% of Burch colposuspension patients. Most cases resolve within 4–8 weeks; persistent dysfunction may require CISC indefinitely or sling revision (sling incision or urethrolysis).
• De novo urgency incontinence (5–20%): New-onset urgency and urge leakage can develop postoperatively, likely related to bladder neck obstruction or altered detrusor dynamics. Managed initially with antimuscarinic agents (e.g., solifenacin) or beta-3 agonists (mirabegron); resistant cases may require cystoscopic evaluation.
• Fascial harvest site complications: Wound haematoma, seroma, infection, or abdominal wall hernia at the rectus sheath harvest site occur in 2–8% of cases. Fascia lata harvest may produce lateral thigh wound complications, numbness in the lateral cutaneous nerve distribution, or gait disturbance during early recovery.
• Persistent or recurrent SUI: Complete continence is not guaranteed; approximately 15–20% of women have residual leakage requiring further management. Options include periurethral bulking agent injection or repeat surgical assessment.
• Bladder or urethral injury during needle passage: Inadvertent cystotomy during retropubic needle passage occurs in approximately 1–3% of cases. This is routinely identified by intraoperative cystoscopy and repaired at the time of surgery, with excellent outcomes if recognised immediately.
• Suture erosion: Permanent sutures used to anchor the sling may occasionally erode through vaginal epithelium; this is less common than synthetic mesh erosion but does occur and may require suture removal.

Preoperative counselling must include explicit discussion of the probability of temporary or permanent CISC if significant voiding dysfunction develops, as acceptance of this risk is essential before proceeding.

Postoperative care following pubovaginal sling surgery is structured to monitor voiding function, assess continence outcomes, manage complications, and support rehabilitation.

• Immediate postoperative period (0–48 hours): A urethral catheter is placed at the end of surgery and removed once the patient is mobile, typically within 24–48 hours. A trial without catheter (TWOC) assesses voiding ability; patients who void with acceptable post-void residual (PVR) below 100 mL are discharged. Those unable to void satisfactorily are trained in clean intermittent self-catheterisation (CISC) before discharge.
• Six-week review: Clinical assessment of voiding function, continence status, wound healing, and patient-reported outcomes. Bladder ultrasound measures PVR. Patients continuing CISC are reviewed; if voiding dysfunction persists beyond 8 weeks without improvement, sling incision or urethrolysis may be considered.
• Three-month assessment: Formal continence evaluation using validated questionnaires (UDI-6, IIQ-7). Pad weight testing may be repeated. Pelvic floor physiotherapy is recommended to consolidate continence and address any de novo urgency symptoms with bladder retraining.
• Long-term surveillance (annually for 2–3 years): Annual review is recommended in women with complex prior history, mesh complications, or ISD. Patients should be advised to report new urgency, haematuria, recurrent UTI, or pelvic pain promptly, as these may indicate late suture erosion, bladder neck obstruction, or recurrent SUI.
• Return to activities: Light daily activities resume at 2–4 weeks. Heavy lifting, high-impact exercise, and penetrative intercourse should be deferred for 6–12 weeks. Women should avoid activities that significantly increase intra-abdominal pressure during early healing.

Ongoing supervised pelvic floor muscle training complements the mechanical support of the sling and is recommended regardless of surgical outcome to optimise long-term continence.

The cost of pubovaginal sling surgery varies significantly by country, hospital setting, and case complexity. Since the procedure uses autologous tissue rather than a purchased implant, material costs are lower than for some synthetic procedures. However, total operative costs are influenced by surgical time, anaesthesia, fascial harvest complexity, and the need for specialist urogynaecological or urological expertise.

• United Kingdom (NHS): Eligible women receive pubovaginal sling surgery on the NHS, funded through the surgical tariff for stress urinary incontinence procedures. Private hospital costs in the UK range from approximately £3,500–£7,000, inclusive of surgeon, anaesthetist, and theatre fees.
• India: Specialist urogynaecological centres in major cities offer the full range of continence surgery. Total costs range from approximately USD 1,200–2,500 (INR 100,000–200,000), making India a widely accessed destination for international patients seeking quality care at reduced cost. Accredited centres in Chennai, Mumbai, Bengaluru, and Delhi provide high-standard operative and postoperative care.
• United States: Out-of-pocket costs range from USD 8,000–18,000 depending on facility type (academic medical centre vs community hospital) and the extent of preoperative urodynamic evaluation. Most major insurance plans cover the procedure with documented SUI following failed conservative management.
• Thailand and Singapore: USD 3,000–6,000 at JCI-accredited institutions, attracting patients from Australia, the Middle East, and South Asia seeking specialist care with shorter wait times.
• Additional cost considerations: Preoperative urodynamic study (USD 400–800), anaesthetic fees, theatre consumables, physiotherapy sessions, potential CISC supplies if voiding dysfunction develops, and postoperative continence pad costs during recovery all contribute to total episode cost.

International patients should prioritise surgeon experience in autologous sling surgery and subspecialty urogynaecological or female urology training rather than basing decisions on cost alone. Many centres offer packaged pricing covering consultation, surgery, inpatient stay, and 30-day follow-up.

Multiple treatment alternatives exist, spanning conservative, minimally invasive, and surgical options. The optimal approach is determined by SUI severity, ISD presence, prior treatment history, and patient preference.

• Supervised pelvic floor muscle training (PFMT): The first-line intervention for all grades of SUI per NICE NG123 and EAU guidelines. A structured 3–6 month programme under a specialist continence physiotherapist produces clinically meaningful improvement in mild to moderate SUI and should be completed before surgical options are considered.
• Mid-urethral synthetic slings (TVT / TOT): Retropubic tension-free vaginal tape (TVT) or transobturator tape (TOT) are the most commonly performed surgical procedures for uncomplicated SUI without significant ISD, with success rates of 80–90% at 1 year in appropriately selected patients. Restricted to specialist NHS mesh centres under NICE 2019 guidance; not appropriate where mesh is declined or contraindicated.
• Burch colposuspension: Open or laparoscopic bladder neck suspension to Cooper's ligament. Avoids mesh entirely, with proven efficacy. The SISTEr trial demonstrated lower overall success than autologous PVS (38% vs 47%); suitable for women without ISD who are undergoing concurrent laparoscopic pelvic surgery.
• Artificial urinary sphincter (AMS 800): The gold standard device for severe ISD (MUCP below 10 cmH2O) or post-radiation SUI. Provides mechanical urethral occlusion with pump-activated voiding release. Continence rates of 80–90% at 5 years are reported; revision rates of 20–30% at 10 years due to mechanical failure or erosion require long-term device surveillance.
• Periurethral bulking agents: Injected submucosal agents — polyacrylamide hydrogel (Bulkamid), calcium hydroxylapatite (Coaptite), or dextranomer/hyaluronic acid (Deflux) — augment urethral coaptation without surgery. Less invasive and suitable for elderly or surgically high-risk patients, but durability is limited (40–60% improvement at 1 year with declining efficacy over time).
• Incontinence pessary: A vaginal continence pessary (e.g., ring with knob, dish pessary) provides non-surgical mechanical support for women who prefer to avoid surgery or are awaiting definitive treatment.

A multidisciplinary continence care pathway including a continence specialist nurse, physiotherapist, and urogynaecologist or female urologist ensures that each patient's treatment plan is individually tailored to her anatomy, urodynamic findings, and personal goals.